title: PNU-282987 improves the hemodynamic parameters by alleviating vasopermeability and tissue edema in dogs subjected to a lethal burns shock.
abstract: Excessive inflammation and high vasopermeability can lead to blood volume loss and tissue edema, which can affect the resuscitation and prognosis for serious burn patients. In this experiment, we investigated the effect of PNU-282987, an α7 nicotine cholinergic receptor agonist on the hemodynamic parameters and survival rate by inhibiting vasopermeability and tissue edema during the fluid resuscitation for lethal burn shock. Forty Beagle dogs with intubation of the carotid artery and jugular vein 24 hours before the injury were subjected to 50% TBSA full-thickness burns, and were randomly divided into following four groups: no resuscitation group (group NR), venous fluid resuscitation group (group R), PNU-282987 treatment group (group P), and fluid resuscitation group plus PNU-282987 group (group RP), with 10 dogs in each group. Hemodynamic variables and biochemical parameters were determined with animals in a conscious and cooperative state. The plasma volume and the vasopermeability were determined by indocyanine green and fluorescein isothiocyanate-dextran, respectively. The level of tumor necrosis factor-α and interleukin-1β in plasma, and the water content of different organs were also determined. The mean arterial pressure, cardiac output, and plasma volume of all dogs decreased significantly, and the lung extravascular water index and pulmonary vascular permeability index increased remarkably after burn. The hemodynamic parameters deteriorated continually in group N dogs, and then anuria, hyperlactacidemia, and multiple organ dysfunctions developed. The mean arterial pressure and cardiac output of dogs in group R and group RP returned to preinjury levels at 48 hours postburn. The lung extravascular water index and pulmonary vascular permeability in group R were higher than those before preinjury. The dogs in group RP were found to have a significant increase in plasma volume and urine output, and a remarkable decrease in the levels of tumor necrosis factor-α, interleukin-1α, lactic acid, and organ functions compared with those of group R (P <.05). The survival rate of RP group (100%; 10/10) was significantly higher than that of group N (0; 0/10), group P (20%; 2/10), and group R (60%; 6/10). PNU-282987 combined with intravenous fluid resuscitation significantly improved hemodynamics and the survival rate in the early period after this lethal burn shock. The mechanism may be attributable to the lowering of the level of proinflammatory mediators, amelioration of vasopermeability-induced visceral edema, less of blood volume loss, and protection of vital organs through activation of cholinergic anti-inflammatory pathway.
authors.affiliation: From the *Burns Institute and †Department of Obstetrics and Gynecology, First Hospital Affiliated to the PLA General Hospital, Beijing, China; and ‡Medical School of Chinese PLA, Beijing, China.
authors.forename: Quan
authors.initials: Q
authors.lastname: Hu
authors.forename: Ming-Hua
authors.initials: MH
authors.lastname: Du
authors.forename: Sen
authors.initials: S
authors.lastname: Hu
authors.forename: Jia-ke
authors.initials: JK
authors.lastname: Chai
authors.forename: Hong-Min
authors.initials: HM
authors.lastname: Luo
authors.forename: Xiao-Han
authors.initials: XH
authors.lastname: Hu
authors.forename: Lin
authors.initials: L
authors.lastname: Zhang
authors.forename: Zhi-Long
authors.initials: ZL
authors.lastname: Lin
authors.forename: Li
authors.initials: L
authors.lastname: Ma
authors.forename: Huan
authors.initials: H
authors.lastname: Wang
authors.forename: Zhi-Yong
authors.initials: ZY
authors.lastname: Sheng
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D001794:Blood Pressure; D001834:Body Water; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology*; D002056:Burns / Q000150:complications*; D002199:Capillary Permeability / Q000187:drug effects*; D002302:Cardiac Output; D003401:Creatine / Q000097:blood; D052279:Creatine Kinase, MB Form / Q000097:blood; D004285:Dogs; D004487:Edema / Q000209:etiology / Q000628:therapy*; D053583:Interleukin-1beta / Q000097:blood; D019344:Lactic Acid / Q000097:blood; D008168:Lung / Q000098:blood supply; D023421:Models, Animal; D018722:Nicotinic Agonists / Q000494:pharmacology*; D010953:Plasma Volume; D011897:Random Allocation; D012151:Resuscitation / Q000379:methods; D012769:Shock / Q000209:etiology*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D014556:Urine
chemical_list: D001549:Benzamides; D001643:Bridged Bicyclo Compounds; D053583:Interleukin-1beta; D018722:Nicotinic Agonists; C498513:PNU-282987; D014409:Tumor Necrosis Factor-alpha; D019344:Lactic Acid; D000410:Alanine Transaminase; D052279:Creatine Kinase, MB Form; D003401:Creatine